Cardiovascular Research Institute, Yokohama City University , Yokohama , Japan.
Department of Medical Life Science, Graduate School of Medical Life Science, Yokohama City University , Yokohama , Japan.
Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H1012-H1018. doi: 10.1152/ajpheart.00329.2018. Epub 2018 Jul 13.
Abdominal aortic aneurysm (AAA) is a life-threatening disease, and no disease-specific circulating biomarkers for AAA screening are currently available. We have identified a smooth muscle cell (SMC)-specific biomarker for AAA. We cultured aneurysmal tunica media that were collected from eight patients undergoing elective open-repair surgeries. Secreted proteins in culture medium were subjected to liquid chromatography/tandem mass spectrometry. Myosin heavy chain 11 (myosin-11) was identified as a SMC-specific protein in the tunica media-derived secretions of all patients. We then examined myosin-11 protein concentrations by ELISA in plasma samples from patients with AAA ( n = 35) and age-matched healthy control subjects ( n = 34). Circulating myosin-11 levels were significantly higher in patients with AAA than control subjects. The area under the receiver-operating characteristic curve (AUC) of myosin-11 was 0.77, with a specificity of 65% at a sensitivity of 91%. Multivariate logistic regression analysis showed a significant association between the myosin-11 level and presence of AAA. When the myosin-11 level was combined with hypertension, it improved the prediction of AAA (AUC 0.88) more than hypertension per se. We then investigated the correlation between aortic diameter and circulating myosin-11 levels using AAA serum samples from patients undergoing endovascular aneurysm repair ( n = 20). Circulating myosin-11 levels were significantly correlated with maximum aortic diameter. Furthermore, changes in myosin-11 concentrations from the baseline 12 mo after endovascular aneurysm repair were associated with those in aortic diameter. These data suggest that circulating levels of myosin-11, which is a SMC-specific myosin isoform, may be useful as a biomarker for AAA. NEW & NOTEWORTHY Extensive studies have revealed that inflammation- or proteolysis-related proteins are proposed as biomarkers for abdominal aortic aneurysm (AAA). Changes in these protein concentrations are not specific for smooth muscle, which is a major part of AAA pathologies. Hence, no disease-specific circulating markers for AAA are currently available. We found, using secretome-based proteomic analysis on human AAA tunica media, that myosin heavy chain 11 was associated with AAA. Circulating myosin heavy chain 11 may be a new tissue-specific AAA marker.
腹主动脉瘤(AAA)是一种危及生命的疾病,目前尚无用于 AAA 筛查的特定疾病的循环生物标志物。我们已经确定了一种用于 AAA 的平滑肌细胞(SMC)特异性生物标志物。我们培养了从 8 名接受择期开放修复手术的患者中收集的动脉瘤中层。对培养基中的分泌蛋白进行液相色谱/串联质谱分析。肌球蛋白重链 11(肌球蛋白-11)被鉴定为所有患者中层来源分泌物中的一种 SMC 特异性蛋白。然后,我们通过 ELISA 检查了 AAA 患者(n=35)和年龄匹配的健康对照者(n=34)的血浆样本中的肌球蛋白-11 蛋白浓度。AAA 患者的循环肌球蛋白-11 水平明显高于对照组。肌球蛋白-11 的受试者工作特征曲线(ROC)下面积(AUC)为 0.77,特异性为 65%,灵敏度为 91%。多变量逻辑回归分析显示,肌球蛋白-11 水平与 AAA 的存在之间存在显著关联。当肌球蛋白-11 水平与高血压相结合时,它比高血压本身更能改善 AAA 的预测(AUC 0.88)。然后,我们使用接受血管内动脉瘤修复的患者的 AAA 血清样本(n=20)研究了主动脉直径与循环肌球蛋白-11 水平之间的相关性。循环肌球蛋白-11 水平与最大主动脉直径显著相关。此外,血管内动脉瘤修复后 12 个月的基线时肌球蛋白-11 浓度的变化与主动脉直径的变化相关。这些数据表明,作为 SMC 特异性肌球蛋白同工型的循环肌球蛋白-11 水平可能可用作 AAA 的生物标志物。新意和值得注意之处:大量研究表明,炎症或蛋白水解相关蛋白被提议作为腹主动脉瘤(AAA)的生物标志物。这些蛋白质浓度的变化不是平滑肌特有的,而平滑肌是 AAA 病理的主要部分。因此,目前尚无用于 AAA 的特定疾病的循环标记物。我们通过对人类 AAA 中层的基于分泌组的蛋白质组学分析发现,肌球蛋白重链 11 与 AAA 相关。循环肌球蛋白重链 11 可能是一种新的组织特异性 AAA 标志物。